Redeye views the positive interim data from the pivotal European trial for ASTar® as excellent. With an EA over 94 percent and CA over 97 percent paired with an overall reproducibility over 99 percent. We were expecting strong results in line with what the company has produced earlier and the process towards the CE-IVD approval. To get the CE-IVD approval, the EA and CA must exceed 90 percent, which the data communicated beats easily We do not expect to change our estimates; however, we are encouraged by the continued strong results presented. We maintain our base case at SEK 180 per share.